-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $65

Benzinga·11/18/2026 13:53:02
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $80 to $65.